VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.880
+0.040 (2.17%)
Aug 28, 2025, 4:00 PM - Market closed

Company Description

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.

It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.

The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.

In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems.

The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.

VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

VivoSim Labs, Inc.
VivoSim Labs logo
CountryUnited States
Founded2007
IndustryBiotechnology
SectorHealthcare
Employees13

Contact Details

Address:
11555 Sorrento Valley Road, Suite 100
San Diego, California 92121
United States
Phone858 224 1000
Websitevivosim.ai

Stock Details

Ticker SymbolVIVS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code0001497253
ISIN NumberUS68620A3023
Employer ID27-1488943
SIC Code2836

Key Executives

NamePosition
Keith E. MurphyExecutive Chairman and Corporate Secretary
Norman StaskeyPresident, Chief Financial Officer and Principal Financial Officer
Dr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy and Business Development
Tony LialinChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Aug 28, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 14, 20258-KCurrent Report
Aug 12, 202510-QQuarterly Report
Jul 29, 202510-K/A[Amend] Annual report
Jun 5, 202510-KAnnual Report
May 15, 2025SCHEDULE 13G/AFiling
May 6, 20258-KCurrent Report
Apr 24, 20258-KCurrent Report
Apr 23, 20258-KCurrent Report
Apr 11, 2025424B5Filing